|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Dopamine agonists: the treatment for Parkinson's disease in the XXI century? 显示文摘 | LLEDó A | 2001 | Parkinsonism Relat Dis2001，7，1： | 1 |
| 2 | Real tine quantification in plasma of human telomerase reverse transcriptase (hTERT)mRNA in patients with colorectal cancer显示文摘 | Lledó SM Garcia-Granero E Dasi F | | 0，，04： | 1 |
| 3 | An Evaluation of the Cardiovascular Safety Profile of Duloxetine Findings from 42 Placebo-Controlled Studies显示文摘 | Wernicke J Lledó A Raskin J | 2007 | Drug Saf2007，30，： | 1 |
| 4 | Determination of vitamins A and E in milk samples by fluorescence in micellar media显示文摘 | Pilar Ramos Lledó Soledad Vera | 2001 | Fresenius J Anal Chem2001，369，： | 1 |
| 5 | BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells显示文摘 | Andreu E J LledóE Poch E | 2005 | Cancer Research2005，65，8： | 1 |
| 6 | BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells显示文摘 | Andreu EJ Lledó E Poch E | 2005 | Cancer Res2005，65，8： | 1 |
| 7 | BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells显示文摘 | ANDREU E J LLEDóE POCH E | 2005 | Cancer Research2005，65，8： | 1 |
| 8 | Influence of occult hepatitis B virus infection in chronic hepatitis C outcomes显示文摘Persistence of hepatitis B virus-DNA in the sera,peripheral blood mononuclear cells or in the liver of hepatitis B surface antigen(HBsAg) -negative patients with or without serological markers of previous exposure(antibodies to HBsAg and/or to HB-core antigen) defines the entity called occult hepatitis B infection(OBI).Co-infection with hepatitis B and hepatitis C viruses is frequent in highly endemic areas.While this co-infection increases the risk of liver disease progression,development of cirrhosis and hepatocellular carcinoma and also increases the rate of therapeutic failure to interferon-based treatments than either virus alone,a potentially negative effect of OBI on clinical outcomes and of therapeutic response to current antiviral regimes of patients with chronic hepatitis C remains inconclusive. | Conrado M Fernandez-Rodriguez Maria Luisa Gutierrez JoséLuis Lledó Maria Luisa Casas | 2011 | World Journal of Gastroenterology2011，17，12： | 3 |
| 9 | Update on the diagnosis and treatment of mirizzi syndrome in laparoscopic era: our experience in 7 years显示文摘 | Lledó JB Barber SM Iba?ez JC | 2014 | Surg Laparosc Endosc Percutan Tech2014，24，6： | 1 |
| 10 | New corneal neovascularization model in rabbits for angiogenesis research显示文摘 | Campos-Mollo E Pérez-Santonja JJ Lledó-Riquelme M | 2011 | Ophthalmic Res2011，45，3： | 1 |
| 11 | Current state of high intensity focused ultrasound (HIFU) as treatment of prostatic carcinoma显示文摘 | Lledó Garcia E Jara Rascón J Herranz Amo F | 2007 | Actas Urol Esp2007，31，6： | 1 |
| 12 | Outpatient laparoscopic cholecystectomy: a new gold standard for cholecystectomy显示文摘 | Bueno Lledó J Planells Roig M Arnau Bertomeu C | 2006 | Rev Esp Enferm Dig2006，98，1： | 1 |
| 13 | Outpatient laparoscopic cholecystectomy:a new gold standard for cholecystectomy显示文摘 | Bueno LledóJ Planells Roig M Arnau Bertomeu C | 2006 | Rev Esp Enferm Dig2006，98，1： | 1 |
| 14 | First percutaneous computed tomographyguided radiofrequency ablation of renal tumor in horseshoe kidney显示文摘 | Husillos-Alonso A Bueno-Chomón G Lledó-García E | 2011 | Urology2011，78，2： | 1 |
| 15 | Acute cholecystitis and laparoscopic cholecystectomy in the elderly显示文摘 | Bueno Lledó J Vaqué Urbaneja J Herrero Bernabeu C | 2007 | Cir Esp2007，81，4： | 1 |
| 16 | Laparoscopic Cholecystectomy and Liver Cirrhosis显示文摘 | Jose Bueno Lledó Jose C. Iba?ez Lucas García Mayor Manuel B. Juan | 2011 | Surgical Laparoscopy Endoscopy & Percutaneous Techniques2011，，6： | 1 |
| 17 | Management of occult hepatitis B virus infection:An update for the clinician显示文摘Occult hepatitis B virus(HBV) infection(OBI) is defined by the presence of HBV DNA in the liver tissue of individuals who test negative for hepatitis B surface antigen(HBsAg).Patients who have recovered from acute hepatitis B can carry HBV genomes for a long time and show histological patterns of mild necro-inflammation,even fibrosis,years after the resolution of acute hepatitis,without showing any clinical or biochemical evidence of liver disease.At least in conditions of immunocompetence,OBI is inoffensive itself,but when other relevant causes of liver damage are present it might make the course of the liver disease worse.The risk of HBV transmission through transfusion is related to blood donations negative for HBsAg that have been collected during the pre-seroconversion period or during chronic OBI.Use of HBV nucleic acid amplification testing and multivalent anti-HBs antibodies in the HBsAg assays is recommended for detection of true and false OBI,respectively.It is not known if prior hepatitis B immunization with an optimal anti-HBs response in cases of HBV transmission through organ transplantation can effectively modulate or abort the infection.Use of anti-viral agents as prophylaxis in patients with serological evidence of past HBV infection prevents reactivation of OBI after transplantation in most cases.Reactivation of OBI has been observed in other conditions that cause immunosuppression,in which antiviral therapy could be delayed until the HBV DNA or HBsAg becomes detectable.OBI might contribute to the progression of liver fibrosis and hepatocellular carcinoma development in patients with chronic liver disease. | JoséLuis Lledó Conrado Fernández María Luisa Gutiérrez Sara Ocaa | 2011 | World Journal of Gastroenterology2011，17，12： | 9 |
| 18 | Bile duct injury during laparoscopic cholecystectomyrid=''显示文摘 | J. Calvete L. Sabater B. Camps A. Verdú A. Gomez-Portilla J. Martín M. A. Torrico B. Flor N. Cassinello S. Lledó | 2000 | Surgical Endoscopy2000，，7： | 2 |
| 19 | Risk Factors for Nonhepatic Surgery in Patients with Cirrhosis显示文摘 | Juan A. Olmo M.D. Blas Flor-Lorente M.D. Blas Flor-Civera M.D. Felicidad Rodriguez M.D. Miguel A. Serra M.D. Amparo Escudero M.D. Salvador Lledó M.D. José M. Rodrigo M.D | 2003 | World Journal of Surgery2003，，6： | 1 |
| 20 | Risk Factors for Nonhepatic Surgery in Patients with Cirrhosis显示文摘 | Juan A. Olmo M.D. Blas Flor-Lorente M.D. Blas Flor-Civera M.D. Felicidad Rodriguez M.D. Miguel A. Serra M.D. Amparo Escudero M.D. Salvador Lledó M.D. José M. Rodrigo M.D | 2003 | World Journal of Surgery2003，，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员